BROOKLYN IMMUNOTHERAPEUTICS
Brooklyn ImmunoTherapeutics operates as a clinical-stage biopharmaceutical company. The Company discovers and develops a novel cytokine-based therapy to treat patients with cancer. Their advanced program is studying the safety and efficacy of IRX-2 in patients with head and neck cancer. In a Phase 2a clinical trial in head and neck cancer, IRX-2 demonstrated an overall survival benefit. The IRX-2 delivers hd-IL-2 and other key cytokines to potentially restore immune function in the tumor microenvironment, enabling the immune system to attack cancer cells. Brooklyn ImmunoTherapeutics serves patients and customers in the State of New York.
BROOKLYN IMMUNOTHERAPEUTICS
Industry:
Biotechnology Health Care Pharmaceutical Therapeutics
Founded:
2018-09-27
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.brooklynitx.com
Total Employee:
11+
Status:
Active
Contact:
(212) 582-1199
Total Funding:
21.18 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Analytics LetsEncrypt Google Tag Manager WordPress Content Delivery Network Google Universal Analytics
Similar Organizations
Aimmune Therapeutics
Aimmune Therapeutics is a clinical-stage biopharmaceutical company that improves the lives of people with food allergies.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Current Employees Featured
Stock Details
Acquisitions List
| Date | Company | Article | Price |
|---|---|---|---|
| 2021-06-14 | Novellus | Novellus acquired by Brooklyn ImmunoTherapeutics | 125 M USD |
| 2021-03-25 | NTN Buzztime | NTN Buzztime acquired by Brooklyn ImmunoTherapeutics | N/A |
| 2018-11-19 | IRX Therapeutics | IRX Therapeutics acquired by Brooklyn ImmunoTherapeutics | N/A |
Key Employee Changes
Official Site Inspections
http://www.brooklynitx.com Semrush global rank: 3.11 M Semrush visits lastest month: 5.17 K
- Host name: 143.198.171.144
- IP address: 143.198.171.144
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Brooklyn ImmunoTherapeutics"
Brooklyn ImmunoTherapeutics Announces Name Change to …
Oct 11, 2022 New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio The Eterna corporate mission is to realize …See details»
Brooklyn ImmunoTherapeutics Announces Name Change to …
Oct 11, 2022 New name reflects Company focus on leveraging exclusively in-licensed foundational mRNA cell engineering patent portfolio. The Eterna corporate mission is to realize …See details»
Brooklyn ImmunoTherapeutics - VentureRadar
LucasPye Bio USA n/a As a Contract Development Manufacturing Organization (CDMO), we fast-track the clinical development of your biologic for regulatory approval, manufacture your …See details»
News - investor.eternatx.com
Nov 7, 2018 For more information about the company and its clinical programs, please visit www.BrooklynITx.com. Media Contact. MacDougall Biomedical Communications Karen …See details»
News - investor.eternatx.com
For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Investor Relations Contact: CORE IR 516-222-2560 [email protected]. Media …See details»
Brooklyn ImmunoTherapeutics - Golden
Organization. Company attributes. Industry. Oncology. Therapeutics. 0. Immunotherapy. Cancer immunotherapy. ... Matt Angel. 0. Legal Name. Brooklyn ImmunoTherapeutics, Inc. Number of …See details»
News - investor.eternatx.com
Apr 29, 2021 For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Forward-Looking Statements. This press release contains forward …See details»
Brooklyn ImmunoTherapeutics Announces Name Change to …
Oct 11, 2022 For more information, please visit www.BrooklynITx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of …See details»
Brooklyn ImmunoTherapeutics Completes Reverse …
Mar 25, 2021 For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Contacts. Media Relations: MacDougall Nicholas Chang [email protected] 781-235-3060See details»
Brooklyn ImmunoTherapeutics Inc. - Cruelty Free Investing
Brooklyn ImmunoTherapeutics, Inc. (Brooklyn), formerly NTN Buzztime, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on cytokine-based therapies in treating …See details»
Brooklyn ImmunoTherapeutics-动脉网
Brooklyn ImmunoTherapeutics专注于探索基于细胞因子的治疗在治疗癌症患者中的作用，既可以作为单一的药物，也可以与其他抗癌疗法相结合。See details»
Brooklyn ImmunoTherapeutics Welcomes Jay Sial as Chief …
NEW YORK, July 13, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that …See details»
Brooklyn ImmunoTherapeutics Establishes Research and ... - Nasdaq
Jun 2, 2021 --Brooklyn ImmunoTherapeutics, Inc., a biopharmaceutical company focused on exploring the role that cytokine and gene editing/cell therapy can have in treating patients with …See details»
Brooklyn ImmunoTherapeutics Acquires License for mRNA …
Apr 29, 2021 Investor Relations: CORE IR 516-222-2560 [email protected]. Media: MacDougall Nicholas Chang [email protected] 781-235-3060 Release Summary.See details»
Eterna Therapeutics LLC
This phase I trial studies the side effects of nivolumab and IRX-2 and how well they work in treating participants with stage III-IVA oral cavity cancer or human papillomavirus (HPV) …See details»
Brooklyn ImmunoTherapeutics Announces Closing of $12 Million …
NEW YORK, March 09, 2022 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) (“Brooklyn”), a biopharmaceutical company focused on exploring the role that …See details»
Brooklyn ImmunoTherapeutics Strengthens Investment in Licensed …
May 24, 2021 Investor Relations Contact: CORE IR 516-222-2560 [email protected] Media Contact: MacDougall Nicholas Chang [email protected] 781-235-3060 Site …See details»
News - investor.eternatx.com
Aug 19, 2021 For more information about Brooklyn and its clinical programs, please visit www.BrooklynITx.com. Investor Relations Contact: CORE IR 516-222-2560 …See details»
Brooklyn ImmunoTherapeutics Announces Publication of Results …
May 11, 2021 Investor Relations Contact : CORE IR 516-222-2560 [email protected]. Source: Brooklyn ImmunoTherapeutics, Inc. In This Story BTX. Market Makers.See details»
Brooklyn ImmunoTherapeutics to Move Stock Exchange Listing to …
Oct 14, 2021 Ticker Symbol to Remain “BTX”NEW YORK, Oct. 14, 2021 (GLOBE NEWSWIRE) -- Brooklyn ImmunoTherapeutics, Inc. (NYSE American: BTX) (“Brooklyn”), a …See details»